Placental Tissue Amendments

SB 275 requires health care providers offering stem cell therapy using placental tissue or perinatal stem cells (not approved by the FDA) to provide patients with a specific written notice before treatment. The notice must be in 40-point type on standard paper, displayed prominently in the office, and included in advertisements. Providers must also obtain a signed consent form detailing the therapy's FDA status, alternatives, risks, and benefits. This bill directly affects providers performing unapproved stem cell therapies and aims to ensure patients receive clear, standardized information about their treatment options.